Gender equity in pharma - celebrating historic women in pharma
As we continue to celebrate the contributions of women in the pharmaceutical field following International Day of Women and Girls in Science and in the lead up to International Women’s Day on March 8, 2023, we take a look at some of the historic pharmaceutical innovations and leadership milestones from women.
American biochemist and pharmacologist Gertrude Elion joined Burroughs–Wellcome (now GSK) in 1944 working in cancer research. During her tenure, she and her team developed the anti-cancer drugs tioguanine and mercaptopurine for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, and acute promyelocytic leukemia, amongst others [i]. In 1978, Elion developed a class of antiviral drugs that more accurately killed a virus without harming health cells. She received the 1988 Nobel Prize in Physiology or Medicine with George H. Hitchins and Sir James Black for innovative drug development techniques known as rational drug design in which biochemical and metabolic differences between human cells and pathogens are targeted [ii].
Frances Oldham Kelsey took a solid stance against rising pressure from pharmaceutical manufacturers in the 60s when thalidomide was reported to cause birth defects in the children of women who ahd taken the drug in Europe. On top of a lack of clinical evidence to support the drug’s safety claims, Kelsey withheld approval in a move that would ultimately prevent further physical deformities in infants. Her resolution to remain firm shaped the FDA’s regulatory procedures, and she was appointed Deputy for scientific and medical affairs for the FDA’s CDER in 1995 [ii].
CEO of GSK Emma Walmsley is the first female CEO of a top 10 pharmaceutical company, where she has replaced 50 of GSK’s top 125 managers in a bid to increase diversity across the board since 2017 [iii]. With business and management experience in the pharmaceutical and consumer products industries, Emma is also a member of the GSK Leadership Team and President and CEO of GSK Consumer Healthcare [i]. In 2020 she was appointed Dame Commander of the British Empire for services to the pharmaceutical industry and business.
Heather Bresch similarly has held the rank of CEO of Mylan since 2021, becoming the first woman to lead a Fortune 500 pharmaceutical company. Various pharmaceutical pricing controversies have plagued the company, such as in 2016 when the EpiPen saw a 400% price hike. While Bresch stated the new pen design was superior, she pushed for the company to introduce another generic pen for half the price. She has also been a trailblazer in lobbying for increased transparency with regards to pharmaceutical pricing. In 2011, she was recognised by Esquire for her role in pushing forward the FDA’s Safety and Innovation Act [i].
[i] Trailblazing Women in Pharma History | Pharma Manufacturing
[ii] Women in the Pharmaceutical Sciences: Honoring Our Pioneers | SpringerLink
[iii] Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth - Bloomberg
Related News
-
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance